Table 2.
Hazard ratios (HRs) and 95% confidence intervals (CIs) for recurrence-free survival (RFS).
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HRs (95% CIs) | p value | HRs (95% CIs) | p value | |
| Age (continuous) | 1.007 (0.957–1.059) | 0.785 | N/A | |
| BMI (continuous) | 1.047 (0.920–1.191) | 0.490 | N/A | |
| ER | 0.239 | N/A | ||
| Negative | 1 | |||
| Positive | 0.574 (0.228–1.446) | |||
| PR | 0.102 | N/A | ||
| Negative | 1 | |||
| Positive | 0.454 (0.176–1.171) | |||
| HER2 | 0.704 | N/A | ||
| Negative | 1 | |||
| Positive | 0.806 (0.265–2.450) | |||
| HG | 0.864 | N/A | ||
| I, II | 1 | |||
| III | 1.044 (0.637–1.711) | |||
| Tumor size | 0.228 | N/A | ||
| ≤ 2 cm | 1 | |||
| > 2 cm | 1.766 (0.701–4.450) | |||
| Lymph node metastasis | 0.037 | 0.597 | ||
| Negative | 1 | 1 | ||
| Positive | 2.689 (1.061–6.815) | 1.404 (0.398–4.954) | ||
| AJCC stage | 0.040 | 0.079 | ||
| I | 1 | 1 | ||
| II | 3.745 (1.192–11.764) | 3.197 (1.015–10.072) | ||
| III | 3.534 (0.791–15.798) | 3.337 (0.745–14.935) | ||
| Lymphovascular invasion | 0.820 | N/A | ||
| Negative | 1 | |||
| Positive | 0.864 (0.246–3.039) | |||
| SUVmean-VAT | 0.041 | 0.023 | ||
| Low | 1 | 1 | ||
| High | 2.928 (1.043–8.215) | 3.361 (1.181–9.566) | ||
| Chemotherapy | 0.543 | N/A | ||
| Not done | 1 | |||
| Done | 0.745 (0.289–1.922) | |||
| Radiotherapy | 0.969 | N/A | ||
| Not done | 1 | |||
| Done | 0.982 (0.387–2.491) | |||
| Endocrine therapy | 0.021 | 0.014 | ||
| Not done | 1 | 1 | ||
| Done | 0.329 (0.127–0.848) | 0.300 (0.115–0.786) | ||
BMI Body mass index; ER Estrogen receptor; PR Progesterone receptor; HER2 Human epidermal growth factor receptor 2; HG Histologic grade; VAT Visceral adipose tissue; N/A Not assessed.